Editorial: does anti-TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question

Ashish Srinivasan; Daniel R. van Langenberg

doi:10.1111/apt.16506

Editorial: does anti-TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question

Ashish Srinivasan, Daniel R. van Langenberg

Eastern Health Clinical School Research

Research output: Contribution to journal › Editorial › Other › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	718-719
Number of pages	2
Journal	Alimentary Pharmacology & Therapeutics
Volume	54
Issue number	5
DOIs	https://doi.org/10.1111/apt.16506
Publication status	Published - Sept 2021

Access to Document

10.1111/apt.16506

Cite this

@article{f7d6559c4d174b36bbb1cd9c090f89ea,

title = "Editorial: does anti-TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question",

author = "Ashish Srinivasan and {van Langenberg}, {Daniel R.}",

note = "Funding Information: AS has served as a speaker for Sandoz and received research support from Pfizer. DvL has received educational grants or research support from Pfizer, Takeda, Ferring, Shire and has received consultancy and/or speaker{\textquoteright}s fees from Pfizer, Janssen, Abbvie, Sandoz, Ferring, Vifor and Emerge Health. Declaration of personal interests: Funding Information: AS is supported by an Australian Government Research Training Program (RTP) scholarship, Monash University Graduate Excellence Scholarship and Monash University Department of Medicine Postgraduate Faculty Award. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = sep,

doi = "10.1111/apt.16506",

language = "English",

volume = "54",

pages = "718--719",

journal = "Alimentary Pharmacology & Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Editorial

T2 - does anti-TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question

AU - Srinivasan, Ashish

AU - van Langenberg, Daniel R.

N1 - Funding Information: AS has served as a speaker for Sandoz and received research support from Pfizer. DvL has received educational grants or research support from Pfizer, Takeda, Ferring, Shire and has received consultancy and/or speaker’s fees from Pfizer, Janssen, Abbvie, Sandoz, Ferring, Vifor and Emerge Health. Declaration of personal interests: Funding Information: AS is supported by an Australian Government Research Training Program (RTP) scholarship, Monash University Graduate Excellence Scholarship and Monash University Department of Medicine Postgraduate Faculty Award. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85112118378&partnerID=8YFLogxK

U2 - 10.1111/apt.16506

DO - 10.1111/apt.16506

M3 - Editorial

C2 - 34379842

AN - SCOPUS:85112118378

SN - 0269-2813

VL - 54

SP - 718

EP - 719

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

IS - 5

ER -

Editorial: does anti-TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question

Access to Document

Other files and links

Cite this